Literature DB >> 11263553

Analysis of potential porcine endogenous retrovirus (PERV) transmission in a whole-organ xenotransplantation model without interfering microchimerism.

M Loss1, H Arends, M Winkler, M Przemeck, G Steinhoff, S Rensing, F J Kaup, H J Hedrich, M E Winkler, U Martin.   

Abstract

The question whether porcine xenografts can lead to porcine endogenous retrovirus (PERV) infection of recipients is critical for the evaluation of the safety of pig-to-man xenotransplantation. Unfortunately, polymerase chain reaction (PCR)-based analysis of potential PERV infections in nonhuman-primate whole-organ xenotransplantation models is hampered by false positive results due to chimeric porcine cells. To avoid the inherent analytical problem of xenomicrochimerism, we developed a non-life-supporting pig-to-primate kidney xenotransplantation model: porcine kidneys were transplanted, whereas the functioning recipient kidneys remained in situ. Subsequent to rejection (after 2 hours to 15 days), xenografts were removed, and recipients remained alive for up to 287 days. Immunosuppressive therapy based on cyclophosphamide, cyclosporine, and steroids was maintained for 28 days after transplantation. Using appropriate PCR assays, xenochimerism was found in tissue samples and partly even in peripheral blood leukocytes (PBLs) while the porcine kidneys were in situ. After graft removal, xenochimerism was no longer detectable, thus allowing analysis for possible PERV transmission.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11263553     DOI: 10.1111/j.1432-2277.2001.tb00006.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  9 in total

Review 1.  Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future.

Authors:  Zhengzhao Liu; Wenbao Hu; Tian He; Yifan Dai; Hidetaka Hara; Rita Bottino; David K C Cooper; Zhiming Cai; Lisha Mou
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

2.  Long-term safety from transmission of porcine endogenous retrovirus after pig-to-non-human primate corneal transplantation.

Authors:  Hyuk Jin Choi; Jiyeon Kim; Jae Young Kim; Hyun Ju Lee; Won Ryang Wee; Mee Kum Kim; Eung Soo Hwang
Journal:  Xenotransplantation       Date:  2017-05-14       Impact factor: 3.907

3.  Mapping full-length porcine endogenous retroviruses in a large white pig.

Authors:  C Herring; G Quinn; R Bower; N Parsons; N A Logan; A Brawley; K Elsome; A Whittam; X M Fernandez-Suarez; D Cunningham; D Onions; G Langford; L Scobie
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Porcine endogenous retrovirus infects but does not replicate in nonhuman primate primary cells and cell lines.

Authors:  Armin Ritzhaupt; Luc J W Van Der Laan; Daniel R Salomon; Carolyn A Wilson
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 5.  Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses.

Authors:  Joachim Denner; Ralf R Tönjes
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

6.  Xenogeneic islet transplantation of microencapsulated porcine islets for therapy of type I diabetes: long-term normoglycemia in STZ-diabetic rats without immunosuppression.

Authors:  Thomas Meyer; Burkhard Höcht; Karin Ulrichs
Journal:  Pediatr Surg Int       Date:  2008-12       Impact factor: 1.827

7.  Mouse retrovirus mediates porcine endogenous retrovirus transmission into human cells in long-term human-porcine chimeric mice.

Authors:  Yong-Guang Yang; James C Wood; Ping Lan; Robert A Wilkinson; Megan Sykes; Jay A Fishman; Clive Patience
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

8.  Susceptibility of porcine endogenous retrovirus to anti-retroviral inhibitors.

Authors:  Takele Argaw; Winston Colon-Moran; Carolyn Wilson
Journal:  Xenotransplantation       Date:  2016-03-29       Impact factor: 3.907

Review 9.  Immune modulation in xenotransplantation.

Authors:  Magdalena Boksa; Joanna Zeyland; Ryszard Słomski; Daniel Lipiński
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-10-30       Impact factor: 4.291

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.